Impact of European benefit-risk reassessment procedures on drug prescribing practices in Denmark

被引：0
|
作者：
Hallgreen, Christine E. [1 ]
Andersen, Morten [1 ]
De Bruin, Marie L. [1 ]
机构：
[1] Univ Copenhagen, Copenhagen, Denmark
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2019年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
965
引用
收藏
页码：468 / 469
页数：2
相关论文
共 50 条
  • [41] Benefit-risk assessment for brincidofovir for the treatment of smallpox: US Food and Drug Administration's Evaluation
    Chan-Tack, Kirk
    Harrington, Patrick
    Bensman, Timothy
    Choi, Su-Young
    Donaldson, Eric
    O'Rear, Julian
    McMillan, David
    Myers, Laine
    Seaton, Mark
    Ghantous, Hanan
    Cao, Yu
    Valappil, Thamban
    Birnkrant, Debra
    Struble, Kimberly
    [J]. ANTIVIRAL RESEARCH, 2021, 195
  • [42] A stochastic multicriteria model for evidence-based decision making in drug benefit-risk analysis
    Tervonen, Tommi
    van Valkenhoef, Gert
    Buskens, Erik
    Hillege, Hans L.
    Postmus, Douwe
    [J]. STATISTICS IN MEDICINE, 2011, 30 (12) : 1419 - 1428
  • [43] The impact of risk minimization measures on compliance and prescribing practices of flupirtine in Germany
    Kaplan, Sigal
    Ehlken, Birgit
    Hamann, Xenia
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (01) : 33 - 40
  • [44] IMPACT OF ELECTRONIC PRESCRIBING IN COMMUNITY-BASED PRACTICES ON POTENTIAL DRUG-DRUG INTERACTIONS
    Fischer, M. A.
    Stedman, M.
    Lii, J.
    Kaushal, R.
    Weissman, J.
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2009, 24 : 98 - 99
  • [45] Drug Promotional Activities in Nigeria: Impact on Prescribing Pattern and Practices of Medical Practitioners
    Fadare, Joseph
    Oshikoya, Kazeem
    Ogunleye, Olayinka
    Desalu, Olufemi
    Enwere, Okezie
    Sunmonu, Taofiki
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 318 - 319
  • [46] THE IMPACT OF ANTIPSYCHOTIC DRUG REGULATIONS ON PSYCHOTROPIC PRESCRIBING PRACTICES IN NURSING-HOMES
    ROVNER, BW
    EDELMAN, BA
    COX, MP
    SHMUELY, Y
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 1992, 149 (10): : 1390 - 1392
  • [47] Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report of an ISPOR Task Force
    Tervonen, Tommi
    Veldwijk, Jorien
    Payne, Katherine
    Ng, Xinyi
    Levitan, Bennett
    Lackey, Leila G.
    Marsh, Kevin
    Thokala, Praveen
    Pignatti, Francesco
    Donnelly, Anne
    Ho, Martin
    [J]. VALUE IN HEALTH, 2023, 26 (04) : 449 - 460
  • [48] Evaluating quantitative benefit-risk analysis for drug-approval decision making in Europe and the United States
    Harmon, Bruno
    Arrighi, Michael
    Johnson, Reed
    Perez, Susana
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 : S26 - S26
  • [49] A comparison of various aggregation functions in multi-criteria decision analysis for drug benefit-risk assessment
    Menzies, Tom
    Saint-Hilary, Gaelle
    Mozgunov, Pavel
    [J]. STATISTICAL METHODS IN MEDICAL RESEARCH, 2022, 31 (05) : 899 - 916
  • [50] A Survey to Assess the Current Status of Structured Benefit-Risk Assessment in the Global Drug and Medical Device Industry
    Gebel, Martin
    Renz, Cheryl
    Rodriguez, Lisa
    Simonetti, Arianna
    Yang, Hong
    Edwards, Brian
    Higginson, James Matthew
    Charpentier, Nicola
    Colopy, Michael
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2024, 58 (04) : 756 - 765
12345